US HB3206 | 2011-2012 | 112th Congress
Status
Spectrum: Moderate Partisan Bill (Republican 14-2)
Status: Introduced on October 14 2011 - 25% progression, died in committee
Action: 2011-10-18 - Referred to the Subcommittee on Health.
Pending: House Subcommittee on Health Committee
Text: Latest bill text (Introduced) [PDF]
Status: Introduced on October 14 2011 - 25% progression, died in committee
Action: 2011-10-18 - Referred to the Subcommittee on Health.
Pending: House Subcommittee on Health Committee
Text: Latest bill text (Introduced) [PDF]
Summary
Cultivating Scientific Expertise to Foster Innovation for Patients Act of 2011 - Amends the Federal Food, Drug, and Cosmetic Act to revise provisions related to financial interests of Food and Drug Administration (FDA) advisory committee members to require the Secretary of Health and Human Services (HHS) to ensure that individual appointments to advisory committees are made to promote scientific and technical expertise while at the same time minimizing any potential conflicts of interest. Requires the Secretary to consider, with respect to any financial interest constituting a potential conflict of interest, the type, nature, and magnitude of the financial interest. Declares that no specific factor shall be dispositive in the Secretary's evaluation of a particular financial interest. Repeals the prohibition specifically applicable to FDA that prevents a member of an advisory committee from participating with respect to a particular matter if such individual or an immediate family member of such individual has a financial interest that could be affected by the advice given to the Secretary.
Title
Cultivating Scientific Expertise to Foster Innovation for Patients Act of 2011
Sponsors
| Rep. Michael Burgess [R-TX] | Rep. John Barrow [D-GA] | Rep. Brian Bilbray [R-CA] | Sen. Marsha Blackburn [R-TN] |
| Rep. Larry Bucshon [R-IN] | Sen. Bill Cassidy [R-LA] | Rep. John Culberson [R-TX] | Rep. Phil Gingrey [R-GA] |
| Rep. Brett Guthrie [R-KY] | Rep. Robert Latta [R-OH] | Rep. Jim Matheson [D-UT] | Rep. Michael McCaul [R-TX] |
| Rep. Erik Paulsen [R-MN] | Rep. Todd Rokita [R-IN] | Rep. John Shimkus [R-IL] | Rep. Greg Walden [R-OR] |
History
| Date | Chamber | Action |
|---|---|---|
| 2011-10-18 | House | Referred to the Subcommittee on Health. |
| 2011-10-14 | House | Referred to the House Committee on Energy and Commerce. |
Subjects
Advisory bodies
Department of Health and Human Services
Drug safety, medical device, and laboratory regulation
Food and Drug Administration (FDA)
Government ethics and transparency, public corruption
Health
Health technology, devices, supplies
Department of Health and Human Services
Drug safety, medical device, and laboratory regulation
Food and Drug Administration (FDA)
Government ethics and transparency, public corruption
Health
Health technology, devices, supplies
US Congress State Sources
| Type | Source |
|---|---|
| Summary | https://www.congress.gov/bill/112th-congress/house-bill/3206/all-info |
| Text | https://www.congress.gov/112/bills/hr3206/BILLS-112hr3206ih.pdf |
